A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism

Psychiatry Research

Volumn 229, Issue 1-2, 2015, Pages 181-187

  Ghaleiha, Ali ^a   Rasa, Soudeh Mohebbi ^b   Nikoo, Mohammadali ^b   Farokhnia, Mehdi ^b   Mohammadi, Mohammad Reza ^b   Akhondzadeh, Shahin ^b  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Autistic Disorder; Inflammation; Pioglitazone; Risperidone

Indexed keywords

PIOGLITAZONE; PLACEBO; RISPERIDONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; NEUROLEPTIC AGENT;

ABDOMINAL PAIN; ABERRANT BEHAVIOR CHECKLIST COMMUNITY; ARTICLE; AUTISM; BEHAVIOR ASSESSMENT; BEHAVIOR DISORDER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPERACTIVITY; INAPPROPRIATE SPEECH; IRRITABILITY; LETHARGY; MALE; NAUSEA; OUTPATIENT CARE; PARALLEL DESIGN; PATIENT COMPLIANCE; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SPEECH DISORDER; STEREOTYPY; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; XEROSTOMIA; AUTISTIC DISORDER; CHILD BEHAVIOR DISORDERS; COMBINATION DRUG THERAPY; DRUG EFFECTS; PSYCHOLOGY;

ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CHILD BEHAVIOR DISORDERS; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRRITABLE MOOD; MALE; PILOT PROJECTS; RISPERIDONE; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84939464397     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.07.043     Document Type: Article

References (32)

1. Ajmone-Cat M.,A., Bernardo A., Greco A., Minghetti L. Non-steroidal anti-inflammatory drugs and brain inflammation: effects on microglial functions. Pharmaceuticals 2010, 3(6):1949-1965.
2. Aman M.G., Singh N.N., Stewart A.W., Field C.J. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am. J. Ment. Def. 1985, 89(5):485-491.
3. Asadabadi M., Mohammadi M.R., Ghanizadeh A., Modabbernia A., Ashrafi M., Hassanzadeh E., Forghani S., Akhondzadeh S. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology 2013, 225(1):51-59.
4. American Psychiatric Association Diagnostic criteria from DSM-IV-TR 2000, American Psychiatric Association, Washington, D.C.
5. Bell J., MacKinlay E., Dick J., MacDonald D., Boyle R., Glen A. Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukotriens Essen. Fatty Acids 2004, 71(4):201-204.
6. Bölte S., Poustka F. Genetic, environmental and immunologic factors in the etiology of autism spectrum disorders. Neuroembryology 2003, 2(4):175-179.
7. Boris M., Kaiser C.C., Goldblatt A., Elice M.W., Edelson S.M., Adams J.B., Feinstein D.L. Effect of pioglitazone treatment on behavioral symptoms in autistic children. J. Neuroinflam. 2007, 4(3):3.
8. Cohly H.H.P., Panja A. Immunological findings in autism. Int. Rev. Neurobiol. 2005, 71:317-341.
9. Drew P.D., Xu J., Storer P.D., Chavis J.A., Racke M.K. Peroxisome proliferator-activated receptor agonist regulation of glial activation: Relevance to CNS inflammatory disorders. Neurochem. Int. 2006, 49(2):183-189.
10. Emanuele E., Lossano C., Politi P., Barale F. Pioglitazone as a therapeutic agent in autistic spectrum disorder. Med. Hypotheses 2007, 69(3):699.
11. Ferré P. The biology of peroxisome proliferator-activated receptors relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53(suppl 1):S43-S50.
12. Ghaleiha A., Ghyasvand M., Mohammadi M.R., Farokhnia M., Yadegari N., Tabrizi M., Hajiaghaee R., Yekehtaz H., Akhondzadeh S. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial. J. Psychopharmacol. 2013, 28(7):677-685.
13. Ghaleiha A., Mohammadi E., Mohammadi M.R., Farokhnia M., Modabbernia A., Yekehtaz H., Ashrafi M., Hassanzadeh E., Akhondzadeh S. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Pediatric Drugs 2013, 15(6):505-514.
14. Hasanzadeh E., Mohammadi M.R., Ghanizadeh A., Rezazadeh S.A., Tabrizi M., Rezaei F., Akhondzadeh S. A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders. Child Psychiatry Hum. Dev. 2012, 43(5):674-682.
15. Klinger L.G., Renner P. Performance-based measures in autism: implications for diagnosis, early detection, and identification of cognitive profiles. J. Clin. Child Psychol. 2000, 29(4):479-492.
16. Leskovec T.J., Rowles B.M., Findling R.L. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv. Rev. Psychiatry 2008, 16(2):97-112.
17. McPheeters M.L., Warren Z., Sathe N., Bruzek J.L., Krishnaswami S., Jerome R.N., Veenstra-VanderWeele J. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 2011, 127(5):e1312-e1321.
18. Mohammadi M.R., Akhondzadeh S. Autism spectrum disorders: etiology and pharmacotherapy. Curr. Drug Therapy 2007, 2(2):97-103.
19. Mohammadi M.R., Yadegari N., Hassanzadeh E., Farokhnia M., Yekehtaz H., Mirshafiee O., Akhondzadeh S. Double-blind placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clin. Neuropharmacol. 2013, 36(6):179-184.
20. Morgan J.T., Chana G., Abramson I., Semendeferi K., Courchesne E., Everall I.P. Abnormal microglial-neuronal spatial organization in the dorsolateral prefrontal cortex in autism. Brain Res. 2012, 1456:72-81.
21. Nazeer A. Psychopharmacology of autistic spectrum disorders in children and adolescents. Pediatric Clin. N. Am. 2011, 58(1):85-97.
22. Nikoo M., Radnia H., Farokhnia M., Mohammadi M.R., Akhondzadeh S. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clin. Neuropharmacol. 2015, 38(1):11-17.
23. Okada K., Yamashita U., Tsuji S. Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy susceptible EL mice. Brain Res. 2006, 1102:175-178.
24. Pardo C.A., Eberhart C.G. The neurobiology of autism. Brain Pathol. 2007, 17(4):434-447.
25. Persico A.M., Bourgeron T. Searching for ways out of the autism maze: genetic epigenetic and environmental clues. Trends Neurosci. 2006, 29(7):349-358.
26. Shah P., Mudaliar S. Pioglitazone: side effect and safety profile. Exp. Opin. Drug Saf. 2010, 9(2):347-354.
27. Swanson C.R., Joers V., Bondarenko V., Brunner K., Simmons H.A., Ziegler T.E., Kemnitz J.W., Johnson J.A., Emborg M.E. The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J. Neuroinflam. 2011, 5:91.
28. Tuchman R., Rapin I. Epilepsy in autism. Lancet Neurol. 2002, 1:352-358.
29. Tetreault N.A., Hakeem A.Y., Jiang S., Williams B.A., Allman E., Wold B.J., Allman J.M. Microglia in the cerebral cortex in autism. J. Autism Dev. Disord. 2012, 42(12):2569-2584.
30. van Neerven S., Kampmann E., Mey J. RAR/RXR and PPAR/RXR signaling in neurological and psychiatric diseases. Prog. Neurobiol. 2008, 85(4):433-451.
31. Vancassel S., Durand G., Barthelemy C., Lejeune B., Martineau J., Guilloteau D., Andrès C., Chalon S. Plasma fatty acid levels in autistic children. Prostaglandins Leukotriens Essen. Fatty Acids 2001, 65(1):1-7.
32. Wiest M.M., German J.B., Harvey D.J., Watkins S.M., Hertz-Picciotto I. Plasma fatty acid profiles in autism: a case-control study. Prostaglandins Leukotriens Essen. Fatty Acids 2009, 80(4):221-227.